Clinical Trials
9 trialsNCT02967692 2025-09-18
COMBI-i
Novartis
Phase 3 Terminated
NCT04261439 2025-05-06
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
Novartis
Phase 1 Terminated
NCT03991130 2025-02-06
High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
University of California, San Diego
Phase 2 Terminated
NCT03009058 2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2 Terminated
NCT04310397 2024-10-30
Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03207867 2024-10-09
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Novartis
Phase 2 Terminated
NCT03301896 2024-06-20
Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Novartis
Phase 1 Terminated
NCT02608268 2023-12-06
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Novartis
Phase 1/2 Terminated
NCT02607813 2022-12-21
Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations
Novartis
Phase 1 Terminated